| Literature DB >> 31615531 |
Qing Yang1, Xue Xin Yu1, Wei Zhang2, Hui Li3.
Abstract
BACKGROUND: The Functional Assessment of Cancer Therapy-Breast (FACT-B) is the most commonly used scale for assessing quality of life in patients with breast cancer. The lack of preference-based measures limits the cost-utility of breast cancer in China. The goal of this study was to explore whether a mapping function can be established from the FACT-B to the EQ-5D-5 L when the EQ-5D health-utility index is not available.Entities:
Keywords: Breast cancer; EQ-5D-5 L; FACT-B; Health utility; Mapping; Quality of life
Mesh:
Year: 2019 PMID: 31615531 PMCID: PMC6792204 DOI: 10.1186/s12955-019-1224-8
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Demographic and clinical characteristics of the study participants
| Characteristic | Groups | N | % |
|---|---|---|---|
| Age, year | <45 | 74 | 16.59 |
| 45~54 | 215 | 48.21 | |
| 55~64 | 138 | 30.94 | |
| ≥65 | 19 | 4.26 | |
| Nationality | Han nationality | 438 | 98.21 |
| Minority | 8 | 1.79 | |
| Education level | Elementary and below | 144 | 32.29 |
| Junior high school | 150 | 33.63 | |
| Senior high school | 88 | 19.73 | |
| Undergraduate or over | 64 | 14.35 | |
| Marital status | Single | 7 | 1.57 |
| Married | 411 | 92.15 | |
| Divorced/separated | 14 | 3.14 | |
| Widowed | 14 | 3.14 | |
| Account location | Rural | 220 | 49.33 |
| Urban | 226 | 50.67 | |
| Health-care insurance | Urban employees | 193 | 43.27 |
| Urban residents | 54 | 12.11 | |
| New rural cooperative scheme | 177 | 29.69 | |
| Other | 22 | 4.93 | |
| Occupation | Public sector employee | 28 | 6.28 |
| Enterprise or company employee/worker | 28 | 6.28 | |
| Self-employed | 23 | 5.16 | |
| Farmer/worker | 123 | 27.58 | |
| Unemployed | 148 | 33.18 | |
| Retiree | 96 | 21.52 | |
| Household income in 2017, Chinese Yuan | <30,000 | 234 | 52.47 |
| 30,000~80,000 | 148 | 33.18 | |
| 80,000~ 150,000 | 45 | 10.09 | |
| ≥150,000 | 19 | 4.26 | |
| Course of disease,month | ≤12 | 133 | 29.82 |
| 13~36 | 147 | 32.96 | |
| 37~60 | 78 | 17.49 | |
| ≥61 | 88 | 19.73 | |
| TNM stage | 0 | 17 | 3.81 |
| I | 72 | 16.14 | |
| II | 224 | 50.22 | |
| III | 99 | 22.20 | |
| IV | 34 | 7.62 | |
| Hormone receptor (ER/PR) | Positive | 306 | 68.61 |
| Negative | 78 | 17.49 | |
| Mixed | 56 | 12.56 | |
| Unkonwn/missing | 6 | 1.35 | |
| HER2 | Positive | 355 | 79.60 |
| Negative | 81 | 18.16 | |
| Unkonwn/missing | 10 | 2.24 | |
| Inpatient/Outpatient | Outpatient | 376 | 84.30 |
| Inpatient | 70 | 15.71 | |
| Surgical therapy | Breast conserving surgery | 101 | 22.65 |
| Modified radical surgery | 331 | 74.22 | |
| Unsurgical | 14 | 3.14 | |
| Chemotherapy | No | 37 | 8.30 |
| Yes | 409 | 91.70 | |
| Radiotherapy | No | 175 | 39.24 |
| Yes | 271 | 60.76 | |
| Targeted therapy | No | 403 | 90.36 |
| Yes | 43 | 9.16 | |
| Endocrine therapy | No | 139 | 31.17 |
| Yes | 307 | 68.83 | |
| Menopause | No | 63 | 14.13 |
| Yes | 383 | 85.87 | |
| Disease state | Primary breast cancer within one year (state P) | 125 | 28.03 |
| Primary and recurrent breast cancer for the second year and above (state S) | 258 | 57.85 | |
| Recurrent breast cancer within one year (state R) | 20 | 4.48 | |
| Metastatic cancer (state M) | 43 | 9.64 |
Fig. 1Histogram of EQ-5D-5 L scores
Fig. 2Histogram of FACT-B scores
Description of EQ-5D-5 L and FACT-B scale scores
| Item | Mean | SD | Median | Maximum | Minimum | Flooring (%) | Ceiling (%) |
|---|---|---|---|---|---|---|---|
| EQ-5D | 0.857 | 0.193 | 0.902 | 1 | − 0.349 | 0 | 25.11 |
| FACT-B | 104.031 | 19.732 | 106 | 146 | 31 | 0 | 0 |
Correlation between EQ-5D-5 L scale and FACT-B scale scores
| Dimension | PWB | SWB | EWB | FWB | BCS | FACT-B total score |
|---|---|---|---|---|---|---|
| Mobility | 0.463* | 0.264* | 0.316* | 0.386* | 0.332* | 0.424* |
| Self-care | 0.535* | 0.203* | 0.245* | 0.254* | 0.285* | 0.316* |
| Usual activities | 0.432* | 0.334* | 0.360* | 0.405* | 0.418* | 0.483* |
| Pain/discomfort | 0.469* | 0.272* | 0.416* | 0.305* | 0.425* | 0.465* |
| Anxiety/depression | 0.488* | 0.378* | 0.643* | 0.428* | 0.533* | 0.627* |
| EQ-5D-5 Ltotal score | 0.601* | 0.389* | 0.558* | 0.471* | 0.545* | 0.642* |
*P<0.001
Coefficient estimates of ordinary least-square regression
| Variable | OLS1 | OLS2 | OLS3 | OLS4 | OLS5 |
|---|---|---|---|---|---|
| Constant | 0.13583*** | 0.02434 | 0.03209 | −0.73772*** | − 0.9110*** |
| FACT-B total score | 0.00693*** | ||||
| PWB | 0.02103*** | 0.02101*** | 0.05172*** | 0.05918*** | |
| SWB | 0.00118 | ||||
| EWB | 0.00368* | 0.00400** | 0.02837*** | 0.01932* | |
| FWB | 0.00386*** | 0.00433*** | 0.01108** | 0.02086*** | |
| BCS | 0.00722*** | 0.00728*** | 0.03138*** | 0.03505*** | |
| Dimension squared | |||||
| PWB squared | −0.00088*** | − 0.00030 | |||
| EWB squared | −0.00076*** | − 0.00029 | |||
| FWB squared | −0.00017*** | 0.00006 | |||
| BCS squared | −0.00045*** | 0.00011 | |||
| Dimension interaction | |||||
| PWB × EWB | 0.00006 | ||||
| PWB × FWB | −0.00019 | ||||
| PWB × BCS | −0.00111*** | ||||
| EWB × FWB | −0.00019 | ||||
| EWB × BCS | −0.00019 | ||||
| FWB × BCS | −0.00036 | ||||
* P<0.10, ** P<0.05, *** P<0.01
Summary of model performance for OLS, Tobit and TPM models
| Model | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
|---|---|---|---|---|---|
| OLS | |||||
| r2 | 0.503 | 0.602 | 0.601 | 0.676 | 0.700 |
| Adjusted r2 | 0.502 | 0.597 | 0.599 | 0.671 | 0.690 |
| RMSE | 0.136 | 0.122 | 0.122 | 0.111 | 0.108 |
| MAD | 0.106 | 0.112 | 0.112 | 0.103 | 0.101 |
| MAE | 0.094 | 0.086 | 0.086 | 0.074 | 0.071 |
| AIC | − 511.486 | −602.471 | − 603.658 | − 687.881 | −705.106 |
| BIC | −503.286 | −577.869 | −583.157 | − 650.979 | −643.601 |
| Tobit model | |||||
| r2 | 0.575 | 0.648 | 0.647 | 0.680 | 0.694 |
| Adjusted r2 | 0.574 | 0.644 | 0.645 | 0.676 | 0.687 |
| RMSE | 0.127 | 0.115 | 0.115 | 0.109 | 0.107 |
| MAD | 0.099 | 0.106 | 0.106 | 0.103 | 0.102 |
| MAE | 0.084 | 0.078 | 0.078 | 0.073 | 0.072 |
| AIC | −131.380 | − 196.891 | −197.837 | −216.597 | − 220.060 |
| BIC | −119.079 | − 168.189 | − 173.235 | − 175.594 | −154.455 |
| Two-part model | |||||
| r2 | 0.534 | 0.615 | 0.614 | 0.674 | 0.695 |
| Adjusted r2 | 0.533 | 0.611 | 0.611 | 0.669 | 0.689 |
| RMSE | 0.132 | 0.120 | 0.112 | 0.110 | 0.106 |
| MAD | 0.110 | 0.113 | 0.114 | 0.102 | 0.099 |
| MAE | 0.087 | 0.081 | 0.082 | 0.072 | 0.071 |
| AIC | − 341.450 | −408.173 | − 410.354 | − 470.352 | − 492.476 |
| BIC | − 333.877 | − 385.306 | − 395.109 | −443.674 | − 454.365 |
Coefficient estimates of Tobit and Two-part model using main effects with or without interaction terms
| Variable | Tobit4 | Tobit5 | Two-part 4 | Two-part 5 | ||
|---|---|---|---|---|---|---|
| First-part | Second-part | First-part | Second-part | |||
| Constant | −0.60177*** | − 0.77881*** | 0.00048 | − 0.81605*** | 4.89e-06 | −1.02358*** |
| FACT-B total score | ||||||
| PWB | 0.04438*** | 0.05329*** | 0.62518** | 0.05972*** | 0.76743 | 0.06598*** |
| EWB | 0.02293** | 0.01407 | ||||
| FWB | 0.00821 | 0.01547 | 0.90802 | 0.02163*** | 0.89512 | 0.03590*** |
| BCS | 0.02609*** | 0.03107*** | 1.55562 | 0.04312*** | 1.78533 | 0.04396*** |
| Dimension squared | ||||||
| PWB squared | −0.00062*** | − 0.00007 | 1.01569*** | − 0.00106*** | 1.01664*** | −0.00033 |
| EWB squared | −0.00057* | − 0.00023 | ||||
| FWB squared | −0.00003 | 0.00013 | 1.00524 | −0.00048*** | 1.00599* | −0.00019 |
| BCS squared | −0.00032* | 0.00018 | 0.99500 | −0.00069*** | 0.99905 | −0.00015 |
| Dimension interaction | ||||||
| PWB × EWB | 0.00001 | |||||
| PWB × FWB | −0.00013 | 1.00542 | −0.00059* | |||
| PWB × BCS | −0.00114*** | 0.98847 | −0.00105*** | |||
| EWB × FWB | −0.00010 | |||||
| EWB × BCS | −0.00005 | |||||
| FWB × BCS | −0.00032 | 0.99508 | −0.00042 | |||
* P<0.10, ** P<0.05, *** P<0.01
Descriptive summary of EQ-5D-5 L utility index derived from observed and predicted values of best fitting models
| Model | Mean | SD | Minimum | P10 | Median | P90 | Maximum | Upper bound(%) |
|---|---|---|---|---|---|---|---|---|
| Observed data | 0.857 | 0.193 | −0.348 | 0.642 | 0.902 | 1 | 1 | 0 |
| OLS4 | 0.857 | 0.158 | −0.213 | 0.663 | 0.905 | 0.972 | 1.005 | 0.897 |
| OLS5 | 0.857 | 0.161 | −0.267 | 0.685 | 0.909 | 0.962 | 0.988 | 0 |
| Tobit4 | 0.852 | 0.156 | −0.157 | 0.648 | 0.902 | 0.963 | 0.985 | 0 |
| Tobit5 | 0.853 | 0.160 | −0.212 | 0.674 | 0.906 | 0.962 | 0.979 | 0 |
| TPM4 | 0.857 | 0.156 | −0.178 | 0.668 | 0.904 | 0.971 | 0.992 | 0 |
| TPM5 | 0.857 | 0.160 | −0.305 | 0.685 | 0.906 | 0.964 | 0.986 | 0 |
Out-of sample 5-fold cross-validation of best fitting models
| Model name | Mean absolute error |
|---|---|
| OLS 4 | 0.07495 |
| OLS 5 | 0.07369 |
| Tobit 4 | 0.08509 |
| Tobit 5 | 0.08319 |
| TPM 4 | 0.07271 |
| TPM 5 | 0.07155 |
Mean actual value and predicted value between different demographic and clinical characteristics patients in 3 best models
| Characteristic | Groups | Actual value | Predicted value | Equated value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OLS5 |
| Tobit5 |
| TPM5 |
| OLS5 |
| |||
| Health-care insurance | Urban employees | 0.871 | 0.870 | 0.002 | 0.866 | 0.003 | 0.869 | 0.002 | 0.872 | 0.002 |
| Urban residents | 0.912 | 0.907 | 0.904 | 0.908 | 0.916 | |||||
| New rural cooperative scheme | 0.825 | 0.826 | 0.822 | 0.827 | 0.820 | |||||
| Other | 0.857 | 0.869 | 0.863 | 0.867 | 0.871 | |||||
| Course of disease, month | ≤12 | 0.809 | 0.821 | <0.001 | 0.817 | 0.001 | 0.819 | <0.001 | 0.814 | <0.001 |
| 13~36 | 0.887 | 0.883 | 0.879 | 0.882 | 0.888 | |||||
| 37~60 | 0.912 | 0.896 | 0.893 | 0.895 | 0.904 | |||||
| ≥61 | 0.831 | 0.833 | 0.829 | 0.836 | 0.828 | |||||
| TNM stage | 0 | 0.900 | 0.897 | 0.051 | 0.893 | 0.072 | 0.896 | 0.144 | 0.905 | 0.051 |
| I | 0.899 | 0.892 | 0.888 | 0.890 | 0.899 | |||||
| II | 0.869 | 0.864 | 0.860 | 0.863 | 0.866 | |||||
| III | 0.844 | 0.835 | 0.831 | 0.835 | 0.831 | |||||
| IV | 0.701 | 0.776 | 0.775 | 0.791 | 0.760 | |||||
| Inpatient/Outpatient | Outpatient | 0.889 | 0.882 | <0.001 | 0.878 | <0.001 | 0.881 | <0.001 | 0.887 | <0.001 |
| Inpatient | 0.685 | 0.723 | 0.720 | 0.726 | 0.696 | |||||
| Endocrine therapy | No | 0.810 | 0.820 | 0.001 | 0.817 | 0.003 | 0.821 | 0.002 | 0.813 | 0.001 |
| Yes | 0.878 | 0.873 | 0.869 | 0.873 | 0.877 | |||||
| Disease state | Primary breast cancer within one year (state P) | 0.814 | 0.818 | <0.001 | 0.814 | <0.001 | 0.816 | <0.001 | 0.811 | <0.001 |
| Primary and recurrent breast cancer for the second year and above (state S) | 0.904 | 0.893 | 0.888 | 0.892 | 0.900 | |||||
| Recurrent breast cancer within one year (state R) | 0.779 | 0.776 | 0.773 | 0.782 | 0.760 | |||||
| Metastatic cancer (state M) | 0.737 | 0.792 | 0.789 | 0.803 | 0.779 | |||||
Fig. 3Observed and predicted EQ-5D-5 L for best fitting models for OLS, Tobit and TPM